Immix Biopharma (NASDAQ:IMMX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note released on Thursday morning, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.

Immix Biopharma Stock Down 8.2 %

NASDAQ:IMMX opened at $1.34 on Thursday. The business’s 50-day moving average price is $1.94 and its two-hundred day moving average price is $2.20. Immix Biopharma has a twelve month low of $1.32 and a twelve month high of $7.75. The stock has a market cap of $35.39 million, a P/E ratio of -1.44 and a beta of 0.12.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. On average, equities research analysts expect that Immix Biopharma will post -0.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC acquired a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned approximately 0.10% of Immix Biopharma at the end of the most recent quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.